We then examined the effect of a small-molecule inhibitor of Bag-1, Thio-2, in Bag-1L-driven premalignant change in this experimental model of ductal carcinoma in situ to determine whether these changes might be amenable to therapeutic intervention. The gene discussed is BAG1; the disease is ductal breast carcinoma in situ.